Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection

J Gastroenterol Hepatol. 2017 Apr;32(4):778-781. doi: 10.1111/jgh.13597.

Abstract

Background and aim: Endoscopic resection is commonly used to remove gastric neoplasms. However, effective dosing or scheduling of proton pump inhibitors for the prevention of delayed bleeding after endoscopic resection remains unclear.

Methods: One hundred sixty-six patients with gastric adenoma or early gastric cancer were enrolled. After an endoscopic procedure, each subject was randomly assigned to 40 mg every 24 h (standard dose group) or 40 mg every 12 h (double-dose group) of intravenous pantoprazole for 48 h. Second-look endoscopy was performed on day 2 after endoscopic resection to compare signs of rebleeding and ulcer status between the two groups.

Result: Eighty-one patients of the standard dose group and 81 of the double-dose group were analyzed. There were no significant differences in the incidence of delayed bleeding events (1.3% vs 6.2%, P = 0.21) and bleeding ulcer at the second-look endoscopy (6.2% vs 3.9%, P = 0.69) between standard and double-dose groups. There were no other significant variables associated with delayed bleeding or bleeding ulcer on second-look endoscopy.

Conclusions: Intravenous pantoprazole 40 mg every 24 h or 12 h for 2 days after endoscopic resection was equally effective for the prevention of delayed bleeding.

Keywords: endoscopic resection; iatrogenic gastric ulcer; proton pump inhibitor.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage*
  • Adenoma / surgery*
  • Aged
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Endoscopy, Gastrointestinal*
  • Female
  • Gastrointestinal Hemorrhage / prevention & control*
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Pantoprazole
  • Postoperative Complications / prevention & control*
  • Prospective Studies
  • Proton Pump Inhibitors / administration & dosage*
  • Reoperation
  • Stomach Neoplasms / surgery*
  • Time Factors
  • Treatment Outcome

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Proton Pump Inhibitors
  • Pantoprazole